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Abstract
Potential risks of COVID-19 spread during minimally invasive procedures caused several concerns among surgeons, despite 
the lack of high-level evidence. Urological robotic and laparoscopic surgery is performed in elective setting in almost all 
occasions, thus allowing adequate planning and stratification. Two high-volume urological centers in Italy performed 77 
robotic and laparoscopic surgeries during the “lockdown” period and adopted various strategies to prevent contamina-
tion. First of all, all patients were tested negative with nasopharyngeal swab before the surgical intervention. Patients and 
personnel were provided adequate personal protective equipment and intraoperative strategies to prevent smoke formation 
and pneumoperitoneum spread were adopted. No patients nor staff members tested positive for COVID-19 during a 15-day 
follow-up period. In conclusion, minimally invasive urologic surgery can be safely performed during the pandemic period 
with adequate planning. We believe that renouncing the benefits of it would be counterproductive, especially in a scenario 
of long-lasting cohabitation with the virus.
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The novel coronavirus pandemic (COVID-19) is presently 
challenging healthcare systems worldwide [1]. Surgical 
practice is adapting and will likely be changing further in 
the future since recent models are suggesting a long-term 
cohabitation with the virus, until effective treatment or vac-
cine become available [2]. In this scenario, several recent 
guidelines have been proposed by International Societies 
regarding surgery during this particular time, with special 
focus on uro-oncologic surgery [3]. In the daily urological 
practice, real life-threatening situations that leave no time for 
adequate surgical planning are rather uncommon. Thus, it is 
unlikely that any urological surgery, in particular Minimally 
Invasive Surgery (MIS) would need to be performed in a 
COVID-19 patient. However, planning and stratification of 
interventions are essential to guarantee an adequate urologi-
cal care, even on an elective basis, without increasing risks 
for patients and healthcare professionals.
Recently, in this Journal, Zheng et al. [4] discussed the 
potential risks of virus spread during minimally invasive 
procedures, providing some general advices to be applied to 
these settings. However, evidence either in favor or against 
the use of MIS after the beginning of COVID-19 pandemic 
is lacking.
Padova Urology Department serves as an academic refer-
ral center in Veneto, Italy. In Padua Province, the first case 
of COVID-19 was reported on February 21st, 2020 and 
the subsequent exponential growth of new cases led to the 
lockdown of the entire Country on March 11th, 2020. Simi-
larly, Udine Hospital is an academic center in Friuli Ven-
ezia Giulia, another region in the North-East of Italy. Both 
Hospitals have served as regional COVID-19 centers, thus 
since the beginning of the COVID-19 spread the Depart-
ments had to re-organize their activity to shift some person-
nel, resources and equipment to the new dedicated COVID 
wards. However, we felt compelled to continue providing 
the usual standards of urological care to our large popula-
tion of patients, while complying to the new regulations. 
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Minimally invasive surgery represents a considerable pro-
portion of ordinary daily practice, accounting for more than 
50% of our major surgeries, performed through robotic or 
laparoscopic approach. Herein, we report about the approxi-
mately 2 months of practice during the COVID-19 “lock-
down” period. In the time period between March 9th, and 
May 1st, 2020, 77 MIS were performed, namely 62 robotic 
and 15 laparoscopic procedures in both centers combined. 
Each intervention was performed by high-experienced sur-
geons with only essential personnel in the operating room, 
with the suspension of unnecessary training and mentoring 
activities. Personal Protective Equipment (PPE) was used by 
staff and patients according to Hospital regulations. Patients 
were tested with nasopharyngeal swab at admission and all 
the Department Staff was tested on a weekly basis as per the 
hospital policy.
No patients tested positive before surgery nor any case of 
COVID-19 amongst those patients was reported by health 
authorities in the following 14 days of potential incubation. 
None of the staff members tested positive during the afore-
mentioned period.
Table 1 summarizes characteristics of patients and inter-
ventions performed.
Several authors recently provided recommendations 
regarding the use of MIS during the COVID-19 pandemic 
that can be summarized in the following points [5, 6]: (1) 
patient testing; (2) personnel protection; (3) reduction of 
smoke formation and spread.
Our experience with MIS and COVID-19 began relatively 
a long time before the publication of the above recommenda-
tions and the choices regulating our activities were based on 
good clinical practice principles. It is noteworthy to point-
out that the procedures applied in our Department match 
what the panels of experts recommended.
1. Testing: when considering elective major surgery (the 
almost totality of urological practice) an appropriate 
screening of patients is mandatory. Provided the non-
deferability of the intervention [3], we believe that 
extensive testing on patients can represent the most 
effective strategy for patient screening, to date. It has 
been reported that the false negative rate of nasopharyn-
geal test may vary between 15 and 25%; as a result a 
negative outcome might not be sufficient for decisions 
on patient management [7]. In addition to the naso-
pharyngeal swab, at admission, every patient was tested 
for body temperature and was required to be asympto-
matic for 7 days prior to surgery and not into contact 
with a known COVID-19 case within the last 14 days. 
In our opinion, this strategy appears to be the most effec-
tive into finding asymptomatic COVID-19 cases, that 
might be at particular risk of surgical complications [8] 
and for whom surgery might be postponed in most of the 
times.
2. Personnel protection: this can be achieved through ade-
quate use of PPE and with the reduction to the minimum 
of the personnel potentially exposed. Adequate use of 
PPE appears essential and mandatory in every type of 
contact with the patient. In our institution, PPE was used 
as prescribed by healthcare authorities and was made 
available for all OR staff according to the institutional 
guidelines. Unnecessary access to OR was suspended 
for all people not directly involved in surgeries, such as 
medical students and product specialists, while training 
and mentoring activities were reduced to a minimum. 
Lastly, periodic testing on every Department staff mem-
ber has been performed and it is still ongoing.
3. Reduction of smoke formation and spread: this particu-
lar aspect is strongly related to the aerosolization of 
particles that might occur during MIS. Zheng et al. [4] 
provided a summary of theoretical risks of spreading the 
virus through the pneumoperitoneum. It is important to 
highlight, however, that this theory is based on papers 
published in the 1990s, on different viruses and that to 
date there is not even anecdotical report of COVID-19 
infection through this route. Additionally, it must be 
noted that filtration of aerosolized particles may be more 
difficult during open surgery, where smoke spreading is 
more likely. Despite the lack of evidence, several authors 
warned against the use of MIS during COVID-19 pan-
demic [9, 10]. In all cases, it is doable and relatively 
easy to adopt strategies to reduce smoke formation and 
spread in the OR as suggested by ERUS guidelines such 
as setting electrosurgery units to the lowest possible set-
Table 1  Summary of minimally invasive surgeries performed
RARP Robot-Assisted Radical Prostatectomy, RAPN Robot-Assisted 
Partial Nephrectomy, VLS VideoLaparoScopic, NUT NephroUreTerc-
tomy




ASA score, N (%)
 1 or 2 63 (81.8)
 3 or 4 14 (18.2)
Type of intervention, N (%)
 RARP 33 (42.8)
 RAPN 26 (33.8)
 VLS Nephrectomy/NUT = 10 (13.0)
 VLS Partial nephrectomy: 4 (5.2)
 Other = 4 4 (5.2)
15-days Complications (Clavien-Dindo > 3), N (%) 6 (7.8)
 COVID-19 Positive patients 0
 COVID-19-positive staff members 0
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tings and careful desufflation of the pneumoperitoneum 
[6]. To prevent potential cross-contamination between 
the patient and the operating room, single-use filters can 
be applied both for the gas insufflation and evacuation. 
Another option is represented by  AirSeal®, that allows 
a filtration with 0.01µ ULPA filter with also a dedicated 
Smoke Evacuation Mode. These strategies, anyhow, are 
generally advisable under all circumstances and not only 
during this acute phase of COVID-19 pandemic.
In our opinion, the evidences against MIS appear not to 
be balanced with its proven benefits. In particular, the lower 
morbidity and short stay in the hospital that characterize 
MIS appear to be a clear advantage in a period when health 
care systems are stressed to the limits. Other aspects that 
should be emphasized are: (1) blood losses are lower in 
MIS compared to open surgery and this aspect is particu-
larly important in a period where blood supplies are lacking, 
due to self-isolation and quarantine. (2) postponed MIS may 
increase the waiting lists with a double effect: a delay in 
diagnosis and treatment with possible disease progressions 
and potential legal issues for hospitals and health systems 
since there is no high level of evidence to justify such a radi-
cal change in ordinary practice. Altogether, these benefits 
could represent the cost-effectiveness of MIS in this time.
We recognize that our observational study does not prove 
any cause–effect relationship and besides strict nasopharyn-
geal swab test protocols, we do not have any serological 
proof of the absence of the contamination. However, in a 
period of time where many questions still wait for a defini-
tive answer, high-level evidences are lacking and, probably, 
will take a long time to become available, even observational 
experiences may provide useful information for the daily 
practice. Based on our set of 77 elective MIS performed dur-
ing the initial COVID-19 pandemic in Italy, we are reporting 
no case of infection in patients or in the staff. Since early on 
we had already adopted a strategy comparable to the recom-
mendations published later on. This resulted in an effec-
tive model to maintain urological care during COVID-19 
pandemic, that is particularly interesting when considering 
the future potentially long-term cohabitation period with the 
virus. On the contrary, the reduction in elective activities 
suggested by some authors [3], appears unrealistic and fails 
to consider the benefits of MIS, some of which are even 
strategically more important during a crisis time.
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